Cannabidiol to reduce social anxiety symptoms
Official title: Investigating the Effects of Cannabidiol on Social Anxiety Disorder
Run by Massachusetts Institute of Technology · NCT05649059 · Data updated 2026-11-12
This will try a single dose of Epidiolex (cannabidiol) to see if it reduces anxiety during a standardized social stress test in adults with social anxiety disorder.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Massachusetts Institute of Technology Academic / other |
| Locations | 1 site (Cambridge, Massachusetts) |
| Status | Recruiting |
| Started | July 10, 2025 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT05649059 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–55 with diagnosed social anxiety disorder, an LSAS score ≥60, right-hand dominance, stable medications, and negative drug and pregnancy tests are ideal candidates.
✕Probably not a fit
People with bipolar disorder, psychosis, recent substance use or cannabis use, significant neurological or medical illnesses (including diabetes), pregnancy, or those outside the age/handedness criteria are unlikely to qualify or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind, placebo-controlled, parallel-group trial will give 50 adults with social anxiety disorder either a single oral dose of Epidiolex (3 mL at 100 mg/mL) or placebo before a Trier Social Stress Test (TSST). Behavioral and physiological measures of anxiety will be recorded during the stress task. After the TSST, participants will undergo fMRI scanning to measure emotional and self-referential brain processing. The study is conducted at MIT with clinical and research support from Massachusetts General Hospital.
Why it matters
Potential benefit: If successful, this could provide a rapid medication option that reduces anxiety during social stress for people with social anxiety disorder.
How similar studies have gone: Previous small studies of single-dose cannabidiol have shown promising anxiety-reducing effects in public-speaking paradigms, but larger controlled evidence remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability and willingness to provide written informed consent. * Sufficiently fluent in English to participate in the trial. * Between 18-55 years of age (inclusive). * Right-hand dominant. * Current medications are stable for past 30 days (no changes to dose or frequency). * Negative result on pregnancy test (if female). * Negative result on urine drug screening. * Liebowitz Social Anxiety Scale (LSAS ≥ 60). Exclusion Criteria: * History of bipolar disorder, schizophrenia, psychosis, delusional disorders. * History of eating disorder within past 6 months. * History of any traumatic brain injury. * Currently diagnosed with diabetes mellitus. * Presence of severe medical illness that would prevent completion of study procedures. * Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia). * History of substance use disorder within past 6 months (other than nicotine and caffeine). * Use of any cannabis-containing products in past 30 days (CBD or THC). * Use of benzodiazepines in past 2 weeks. * Use of alpha- or beta-blockers in past week. * History of claustrophobia. * Contraindications for MRI (e.g.; shrapnel). * Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures. * Use of concomitant medication that has a strong interaction with CBD. * History of liver disease. * History of hypersensitivity to cannabinoids. * History of hypersensitivity to sesame seed oil. * Currently breastfeeding (if female).
Where it's running
-
Massachusetts Institute of Technology
Cambridge, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: John Gabrieli, PhD — Massachusetts Institute of Technology
- Study coordinator: Omar Rutledge, MS
- Email: orutledge@mit.edu
- Phone: 617-324-2898
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Wearable exosuit to help people with knee osteoarthritis move more
This study tests a wearable exoskeleton (Dephy Exoboot) to see if it helps adults with knee osteoarthritis walk more and reduce pain.
-
Powered ankle prosthesis with neural control and skin feedback for people with lower-leg amputation
A powered ankle prosthesis that uses neural signals and skin stimulation to help people with a transtibial amputation walk more naturally.
-
40Hz light, sound, and touch stimulation to change brain activity in people with and without Alzheimer's disease.
This one-day visit will test whether non-invasive 40Hz light, sound, and touch stimulation can change brain activity, connectivity, and blood markers in cognitively normal adults and people with Alzheimer's disease.
-
Neural-controlled powered knee and ankle for people with above-knee amputation.
We will test whether a neural-controlled powered knee or ankle prosthesis helps people with above-knee (transfemoral) amputation walk more naturally and stably in everyday situations.
-
Outreach program to improve engagement in a wellness initiative for metabolic syndrome
This study is testing if a new way of inviting people to join a wellness program can help those with metabolic syndrome get better support for weight management and diabetes prevention.
-
Using light and sound therapy to treat Alzheimer's disease
This study is testing whether a light and sound device can help people with mild Alzheimer's disease improve their memory and brain function over six months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.